{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:21:46Z","timestamp":1792272106213,"version":"4.4.0"},"reference-count":93,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Advances in molecular pathology have transformed NSCLC (Non-Small Cell Lung Cancer) diagnosis, prognosis, and treatment by enabling precise tumor characterization and targeted therapeutic strategies. We review key genomic alterations in NSCLC, including EGFR (epidermal growth factor receptor) mutations, ALK (anaplastic lymphoma kinase) and ROS1 (ROS proto-oncogene 1) rearrangements, BRAF (B-Raf proto-oncogene serine\/threonine kinase) mutations, MET (mesenchymal\u2013epithelial transition factor) alterations, KRAS (Kirsten rat sarcoma) mutations, HER2 (human epidermal growth factor receptor 2) alterations and emerging NTRK (neurotrophic receptor tyrosine kinase) fusions and AXL-related pathways. Methods: A total of 48 patients with NSCLC was analyzed, including 22 women and 26 men (mean age 70 years, range 44\u201386). Tumor specimens were classified histologically as adenocarcinomas (n = 81%) or squamous cell carcinomas (n = 19%). Smoking history, PD-L1 (programmed death-ligand 1) expression, and genetic alterations were assessed. NGS (Next-generation sequencing) identified genomic variants, which were classified according to ACMG (American College of Medical Genetics and Genomics) guidelines. Results: The cohort consisted of 29 former smokers, 13 current smokers, and 5 non-smokers (12%), with a mean smoking burden of 33 pack years. PD-L1 TPS (tumor proportion score) was \u226550% in 10 patients, \u22651\u2013&lt;50% in 22, and &lt;1% in 15 patients. In total, 120 genomic variants were detected (allele frequency \u2265 5%). Of these, 52 (43%) were classified as likely pathogenic or pathogenic, 48 (40%) as variants of unknown significance, and 20 (17%) as benign or likely benign. The most frequently altered genes were TP53 (tumor protein p53) (31%), KRAS and EGFR (15% each), and STK11 (serine\/threonine kinase 11) (12%). Adenocarcinomas accounted for 89% of all alterations, with TP53 (21%) and KRAS (15%) being most common, while squamous cell carcinomas predominantly harbored TP53 (38%) and MET (15%) mutations. In patients with PD-L1 TPS \u2265 50%, KRAS mutations were enriched (50%), particularly KRAS G12C and G12D, with frequent co-occurrence of TP53 mutations (20%). No pathogenic EGFR mutations were detected in this subgroup. Conclusions: Comprehensive genomic profiling in NSCLC revealed a high prevalence of clinically relevant mutations, with TP53, KRAS and EGFR as the dominant drivers. The strong association of KRAS mutations with high PD-L1 expression, irrespective of smoking history, highlights the interplay between genetic and immunological pathways in NSCLC. These findings support the routine implementation of broad molecular testing to guide precision oncology approaches in both adenocarcinoma and squamous cell carcinoma patients.<\/jats:p>","DOI":"10.3390\/cancers18020216","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:15:50Z","timestamp":1767968150000},"page":"216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions"],"prefix":"10.3390","volume":"18","author":[{"given":"Melanie","family":"Winter","sequence":"first","affiliation":[{"name":"Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"},{"name":"University Hospital Frankfurt MVZ GmbH, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Jeroch","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt MVZ GmbH, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wetz","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0940-0521","authenticated-orcid":false,"given":"Marc-Alexander","family":"Rauschendorf","sequence":"additional","affiliation":[{"name":"Molecular Health, Kurfuersten-Anlange 21, 69115 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"},{"name":"University Hospital Frankfurt MVZ GmbH, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref_1","unstructured":"Clark, S.B., and Alsubait, S. (2025). Non\u2013Small Cell Lung Cancer. StatPearls [Internet], StatPearls Publishing."},{"key":"#cr-split#-ref_2.1","unstructured":"Robert-Koch-Institut (2023). Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID)"},{"key":"#cr-split#-ref_2.2","unstructured":"Zentrum f\u00fcr Krebsregisterdaten des RKI (ZfKD). Krebs in Deutschland 2019\/2020, Robert-Koch-Institut. [14th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Burt, J.R., Qaqish, N., Stoddard, G., Jridi, A., Sage Anderson, P., Woods, L., Newman, A., Carter, M.R., Ellessy, R., and Chamberlin, J. (2025). Non-small cell lung cancer in ever-smokers vs never-smokers. BMC Med., 23.","DOI":"10.1186\/s12916-024-03844-8"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41416-024-02592-z","article-title":"Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity","volume":"130","author":"Blechter","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e32899","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kumbrink, J., Demes, M.C., Jeroch, J., Br\u00e4uninger, A., Hartung, K., Gerstenmaier, U., Marienfeld, R., Hillmer, A., Bohn, N., and Lehning, C. (2024). Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting. Pathol. Oncol. Res., 30.","DOI":"10.3389\/pore.2024.1611590"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00292-019-0605-4","article-title":"Nationales Netzwerk Genomische Medizin. Das nationale Netzwerk Genomische Medizin (nNGM): Modell f\u00fcr eine innovative Diagnostik und Therapie von Lungenkrebs im Spannungsfeld eines \u00f6ffentlichen Versorgungsauftrages [The national Network Genomic Medicine (nNGM): Model for innovative diagnostics and therapy of lung cancer within a public healthcare system]","volume":"40","author":"Wolf","year":"2019","journal-title":"Pathologe"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Singh, R.R. (2022). Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071539"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/EDBK_209089","article-title":"Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation","volume":"38","author":"Brown","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_12","first-page":"503","article-title":"Lung cancer biomarkers, targeted therapies and clinical assays","volume":"4","author":"Patel","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41698-021-00237-5","article-title":"Selective KRAS G12C inhibitors in non-small cell lung cancer: Chemistry, concurrent pathway alterations, and clinical outcomes","volume":"5","author":"Palma","year":"2021","journal-title":"Npj Precis. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102957","DOI":"10.1016\/j.ctrv.2025.102957","article-title":"Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC)\u2014Biology, clinical results and future directions","volume":"137","author":"Attili","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","first-page":"PO.20.00516","article-title":"MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19347","DOI":"10.1038\/s41598-025-99541-4","article-title":"MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience","volume":"15","author":"Dhiab","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11912-025-01640-y","article-title":"NRG1 Fusions: The New Kid on the Block","volume":"27","author":"Gupta","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","unstructured":"(2025, October 07). Qiagen: QIAamp\u00ae DNA Micro Handbook, Third Edition, December 2014. Available online: https:\/\/www.qiagen.com\/us\/resources\/resourcedetail?id=085e6418-1ec0-45f2-89eb-62705f86f963&lang=en."},{"key":"ref_20","unstructured":"(2025, October 07). Maxwell, RSC RNA FFPE Kit, Quick Protocol, PART #9FB184. Available online: https:\/\/www.promega.de\/en\/products\/nucleic-acid-extraction\/rna\/maxwell-rsc-rna-ffpe-kit\/?catNum=AS1440#protocols."},{"key":"ref_21","unstructured":"(2025, October 07). ThermoFisher Scientific: Qubit\u2122 RNA HS Assay Kit, Rev. B. Available online: https:\/\/documents.thermofisher.com\/TFS-Assets\/LSG\/manuals\/Qubit_RNA_HS_Assay_UG.pdf."},{"key":"ref_22","unstructured":"(2025, October 07). ThermoFisher Scientific: Qubit\u2122 1X dsDNA HS Assay Kit, Rev. C. Available online: https:\/\/assets.thermofisher.com\/TFS-Assets\/LSG\/manuals\/MAN0017455_Qubit_1X_dsDNA_HS_Assay_Kit_UG.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"D835","DOI":"10.1093\/nar\/gkz972","article-title":"ClinVar: Improvements to accessing data","volume":"48","author":"Landrum","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: A curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_27","unstructured":"McEntyre, J., and Ostell, J. (2025, October 07). The Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation, The NCBI Handbook [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK21088\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_29","unstructured":"(2025, November 12). HGVS Nomenclature, 21.1 Series. Available online: https:\/\/hgvs-nomenclature.org\/stable\/."},{"key":"ref_30","unstructured":"(2025, November 12). Agilent Technologies Inc, PD-L1 IHC 22C3 pharmDx (Dako), 29435 (2023JAN10). Available online: https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29435-d66799-pd-l1-ihc22c3-nsclc-int-man-en.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","article-title":"STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?","volume":"157","author":"Parisi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108058","DOI":"10.1016\/j.lungcan.2024.108058","article-title":"STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status","volume":"199","author":"Favorito","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"djt356","DOI":"10.1093\/jnci\/djt356","article-title":"Wnt signaling pathway in non-small cell lung cancer","volume":"106","author":"Stewart","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s12967-024-05380-8","article-title":"Wnt\/\u03b2-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ctrv.2013.08.006","article-title":"Strategies for co-targeting the PI3K\/AKT\/mTOR pathway in NSCLC","volume":"40","author":"Heavey","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cancers7020816","article-title":"Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK","volume":"7","author":"Rothschild","year":"2015","journal-title":"Cancers"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3608241","DOI":"10.1155\/2020\/3608241","article-title":"Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed Res. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0b013e31822944b3","article-title":"Novel therapeutic targets in non-small cell lung cancer","volume":"6","author":"Janku","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.12490","article-title":"Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)","volume":"20","author":"Kumarakulasinghe","year":"2015","journal-title":"Respirology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Halvorsen, A.R., Silwal-Pandit, L., Meza-Zepeda, L.A., Vodak, D., Vu, P., Sagerup, C., Hovig, E., Myklebost, O., B\u00f8rresen-Dale, A.L., and Brustugun, O.T. (2016). TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. Front. Genet., 07.","DOI":"10.3389\/fgene.2016.00085"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, F., Wang, B., Wu, M., Zhang, L., and Ji, M. (2025). Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: A systematic review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1509173"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1039\/D0MD00096E","article-title":"KRasG12C inhibitors in clinical trials: A short historical perspective","volume":"11","author":"Goebel","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bjc.2015.356","article-title":"Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: A systematic review and meta-analysis","volume":"113","author":"Kuan","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"602","DOI":"10.21037\/jtd-22-177","article-title":"Treatment strategy of EGFR-mutated non-small cell lung cancer","volume":"14","author":"Tanaka","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1093\/oncolo\/oyad111","article-title":"Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer with Uncommon EGFR Mutations: A Pooled Analysis","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jtho.2022.07.148","article-title":"MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC","volume":"17","author":"MacMahon","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/ajhp\/zxaa197","article-title":"Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness","volume":"77","author":"Hirsh","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1\/2 Open-label Nonrandomized Clinical Trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"G\u00e1lffy, G., Mor\u00f3cz, \u00c9., Korompay, R., H\u00e9cz, R., Bujdos\u00f3, R., Pusk\u00e1s, R., Lovas, T., G\u00e1sp\u00e1r, E., Yahya, K., and Kir\u00e1ly, P. (2024). Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol. Oncol. Res., 30.","DOI":"10.3389\/pore.2024.1611715"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.7150\/jca.65370","article-title":"Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma","volume":"13","author":"Wu","year":"2022","journal-title":"J. Cancer"},{"key":"ref_58","first-page":"149","article-title":"Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement","volume":"4","author":"Kim","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/14737140.2023.2265566","article-title":"Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure","volume":"23","author":"Fukuda","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/COC.0000000000001088","article-title":"Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments","volume":"47","author":"Xu","year":"2024","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent Advances in Targeting ROS1 in Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S686","DOI":"10.1016\/j.jtho.2021.01.1261","article-title":"Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients","volume":"16","author":"Xu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/pcm-20-20","article-title":"Cases of ROS1-rearranged lung cancer: When to use crizotinib, entrectinib, lorlatinib, and beyond?","volume":"3","author":"Sehgal","year":"2020","journal-title":"Precis Cancer Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41698-025-01089-z","article-title":"Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment","volume":"9","author":"Lu","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e34654","DOI":"10.1097\/MD.0000000000034654","article-title":"A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer","volume":"103","author":"Chimbangu","year":"2024","journal-title":"Medicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e6552","DOI":"10.1097\/MD.0000000000006552","article-title":"A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer","volume":"96","author":"Cui","year":"2017","journal-title":"Medicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"T\u00f3th, L.J., Mok\u00e1nszki, A., and M\u00e9hes, G. (2024). The rapidly changing field of predictive biomarkers of non-small cell lung cancer. Pathol. Oncol. Res., 30.","DOI":"10.3389\/pore.2024.1611733"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_77","unstructured":"(2025, December 29). Atezolizumab (Neues Anwendungsgebiet, NSCLC, Hohe PD-L1 Expression), Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln Gem\u00e4\u00df \u00a7 35a SGB V, AIO\/DGP\/DGHO, Vorgangsnummer 2022-07-15-D-828, IQWiG Bericht Nr. 1435, ver\u00f6ffentlicht 15,10,2022. Available online: https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/atezolizumab\/atezolizumab-aio-dgho-dgp-nsclc-stellungnahme-20221107.pdf."},{"key":"ref_78","unstructured":"Julia, S., Marius, G., Andreas, W., Ina, M., Paul, B., Nicole, S., and Mario, C. (2025, December 29). Immune Checkpoint Inhibitors for the Treatment of Adult Solid Cancer Patients in the Palliative 1st Line Setting, WHO Collaborating Center on Evidence Synthesis and Evaluation of Novel Cancer Therapies and Institute of Public Health, Medical Faculty and University Hospital Cologne University of Cologne, Germany. Available online: https:\/\/cdn.who.int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-021-03030-2","article-title":"EGFR mutation status in non-small cell lung cancer receiving PD-1\/PD-L1 inhibitors and its correlation with PD-L1 expression: A meta-analysis","volume":"71","author":"Yang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.18632\/oncotarget.23969","article-title":"Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: A meta-analysis","volume":"9","author":"Lan","year":"2018","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.31557\/APJCP.2022.23.1.131","article-title":"Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype","volume":"23","author":"Pandey","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Liam, C.K., Yew, C.Y., Pang, Y.K., Wong, C.K., Poh, M.E., Tan, J.L., Soo, C.I., Loh, T.C., Chin, K.K., and Munusamy, V. (2023). Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11156-y"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","article-title":"Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u226550","volume":"69","author":"Cortellini","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2311966","DOI":"10.1001\/jamanetworkopen.2023.11966","article-title":"Prediagnosis Smoking Cessation and Overall Survival Among Patients with Non-Small Cell Lung Cancer","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/07853890.2022.2124449","article-title":"Sex difference in response to non-small cell lung cancer immunotherapy: An updated meta-analysis","volume":"54","author":"Liang","year":"2022","journal-title":"Ann. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/1759-7714.15336","article-title":"PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population","volume":"15","author":"Sarova","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/aje\/kwx339","article-title":"Sex Differences in Risk of Smoking-Associated Lung Cancer: Results from a Cohort of 600,000 Norwegians","volume":"187","author":"Hansen","year":"2018","journal-title":"Am. J. Epidemiol."},{"key":"ref_91","unstructured":"(2025, October 07). S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 4.0\u2014M\u00e4r 2025, AWMF-Registernummer: 020-007OL. Available online: https:\/\/hub.leitlinienprogramm-onkologie.de\/leitlinie\/praevention-diagnostik-therapie-und-nachsorge-des-lungenkarzinoms."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:56:42Z","timestamp":1768456602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020216"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020216","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}